KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Prepaid Assets (2016 - 2025)

Alnylam Pharmaceuticals' Prepaid Assets history spans 17 years, with the latest figure at $281.9 million for Q4 2025.

  • For Q4 2025, Prepaid Assets rose 141.01% year-over-year to $281.9 million; the TTM value through Dec 2025 reached $281.9 million, up 141.01%, while the annual FY2025 figure was $281.9 million, 141.01% up from the prior year.
  • Prepaid Assets reached $281.9 million in Q4 2025 per ALNY's latest filing, up from $188.0 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $281.9 million in Q4 2025 to a low of $76.0 million in Q1 2021.
  • Average Prepaid Assets over 5 years is $140.4 million, with a median of $131.3 million recorded in 2022.
  • The largest YoY upside for Prepaid Assets was 141.01% in 2025 against a maximum downside of 24.53% in 2025.
  • A 5-year view of Prepaid Assets shows it stood at $88.1 million in 2021, then soared by 50.91% to $132.9 million in 2022, then decreased by 4.92% to $126.4 million in 2023, then dropped by 7.45% to $117.0 million in 2024, then skyrocketed by 141.01% to $281.9 million in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Prepaid Assets are $281.9 million (Q4 2025), $188.0 million (Q3 2025), and $147.3 million (Q2 2025).